On April 25, 2025, the FDA issued a denial letter regarding CytoSorbents’ (NASDAQ:CTSO) De Novo Request for DrugSorb-ATR authorization. The agency identified remaining deficiencies that must be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results